Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that aminoguanidine induced increased VEGF mRNA expression in stored hair follicle micrografts, suggesting potential for developing growth-promoting storage solutions in hair restoration surgery.

In this study, A. capillus-veneris solution demonstrated potential to reduce hair loss and improve hair characteristics in a testosterone-induced alopecia mouse model.

This study concluded that using a multimedia patient education tool may improve patient comprehension of platelet-rich plasma treatment for androgenetic alopecia in a dermatology practice.

This review discusses the potential of augmented reality to advance vascular and endovascular surgery by improving 3D anatomical understanding and reducing patient risk, but notes that further research is needed to overcome current technological limitations.

This study found that androgen receptor signaling is linked to blood vessel regression in the dermal papilla of balding scalp, contributing to hair follicle miniaturization in androgenetic alopecia.

This study introduced and validated the VESALT, a visual extension of the Severity of Alopecia Tool, finding it offers improved reliability and user-friendliness over SALT by incorporating pattern recognition and broader coverage, including non-scalp regions, in assessing alopecia areata severity.

This article describes viDA Therapeutics Inc.'s focus on developing new drugs for age-related conditions using their proprietary granzyme-based approach but reports no clinical outcomes, primarily discussing their funding and business strategy.

This study found that injecting highly purified monocyto-angiotropin into hare skin induced new blood vessel formation and significantly accelerated hair growth at the injection site compared to control areas.

This study found that the heartwood extract of Avicennia marina demonstrated strong antioxidant activity, with an IC50 value of 61.50 µg/mL, suggesting potential for development into supplements or topical applications targeting degenerative diseases related to oxidative stress.

This review discusses androgenetic alopecia and existing treatments, reporting no new clinical results; the authors highlight promising prospects for androgen receptor degrader drugs among therapeutic options.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

This study found that 0.75% adenosine lotion significantly improved hair growth and thickness in Japanese women with female pattern hair loss compared to a placebo.

This study describes a case series where combining PRP and stromal vascular fraction cells for androgenic alopecia led to denser hair growth and improved hair quality in three patients.

This study found that water fractions of Angiopteris evecta stimulated hair growth in male rabbits, suggesting potential alopecia treatment benefits pending further research in humans.

In this study, a risk score was developed and validated to identify patients at high risk of clinical failure after femoropopliteal peripheral vascular intervention, aiming to guide the selection of patients who may benefit from paclitaxel-coated devices or alternative strategies.

This study developed a stable nanoemulsion of Avicennia marina heartwood extract showing promising anti-dandruff activity against Pityrosporum ovale and favorable physicochemical properties, which supports its potential use in topical formulations.

This review explores the cellular dynamics of graft rejection in vascularized composite allotransplantation and discusses how understanding these processes might lead to innovative treatments for managing rejection.

Androgenetic alopecia (AGA) is a common, hereditary hair loss condition that can be slowed but not permanently reversed with available therapies.

This review discusses female androgenic alopecia, highlighting its potential difference from male androgenic alopecia and notes increased incidence, but reports no new clinical findings.

This study developed a sensitive HPLC-MS/MS method for determining cyproterone acetate levels in human plasma and found no significant difference in its concentration between two oral formulations in bioequivalence testing.

This study reported that treatments using ADSC-CM improved hair growth in all participants, with the most pronounced results after four sessions within three to four months.

This study found that the rs3185480 polymorphism in the APCDD1 gene was associated with an elevated risk of developing androgenic alopecia and reduced protein levels, potentially due to altered codon usage affecting translation efficiency.

This study showed that men with androgenetic alopecia had higher serum levels of testosterone and DHT compared to controls, but no difference in PSA levels.

This study identifies two new proteins, CCDC22 and CCDC93, essential for root and root hair growth in Arabidopsis, and demonstrates their genetic link to a VTI13-dependent vacuolar trafficking pathway.

This study found that topical valproic acid significantly increased hair count in male patients with moderate androgenetic alopecia compared to placebo over 24 weeks.

This study explores the clinical significance of the intravesical prostatic protrusion/prostate volume ratio in diagnosing bladder outlet obstruction but reports no new results.

In this study, researchers presented a novel therapeutic approach for androgenetic alopecia combining AR-PROTAC degradation with regenerative strategies and evaluated the potential of GT20029 as a topical treatment, proposing a three-phase protocol and future research hypotheses.

In this study, researchers identified two independent genetic variants near the androgen receptor gene strongly associated with androgenetic alopecia in men.

In this case series, researchers reported an unexpectedly rapid and positive response to a topical, hydrogel-based botanical treatment for androgenetic alopecia in both male and female volunteers, achieving significant improvement in hair loss within 90 days instead of the planned 270 days.

This study found that androgenetic alopecia treatments, especially dutasteride, are associated with a small increased risk of adverse events like sexual dysfunction and dermatologic reactions.